Categories
Change Password!
Reset Password!
Involvement of Janus Kinase 1 (JAK1) pathways has already been reported in the pathogenesis of psoriatic arthritis.
Filgotinib is an oral JAK inhibitor that differs from previously characterized tsDMARDs as it is selective for JAK1 over other JAK family members. In this study, filgotinib, which is a selective JAK1 inhibitor is efficacious for psoriatic arthritis treatment in patients with active disease. There were rapid improvements in multiple domains of PsA disease activity, including enthesitis and patient-reported outcomes.
Involvement of Janus Kinase 1 (JAK1) pathways has already been reported in the pathogenesis of psoriatic arthritis. In this study, efficacy and safety of a selective JAK1 inhibitor, filgotinib for the treatment of psoriatic arthritis has been investigated.
A randomized, double-blinded, placebo-controlled phase 2 trial, by the name of EQUATOR, was conducted on adults from 25 sites in the seven European countries. The subjects were 18 plus years old with active psoriatic arthritis and having a failure to respond to a minimum of one csDMARD (conventional synthetic disease-modifying anti-rheumatic drug). Patients were equally divided into filgonitib 200 mg group and placebo group for 16 weeks. The patients achieving a 20% improvement in ACR20 at week 16 was assigned primary endpoint.
Out of total of 191 patients screened, 131 were randomly divided into filgotinib group (n=65) and placebo group (n=65). 80% of the patients in the filgotinib group achieved ACR20 at week 16 compared to 33% patients achieving ACR20 at week 16 in the placebo group. 57% of patients in the filgotinib group and 59% of patients in placebo faced adverse events. One serous treatment-inducing adverse event which was pneumonia and hip fracture after a fall emerged in each group.
Filgotinib is reportedly highly effective in psoriatic arthritis treatment compared to placebo with least adverse events.
The Lancet
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomized, placebo-controlled, phase 2 trial
Philip Mease et al.
Comments (0)